This review outlines Phase II clinical trial methodology for evaluating new antitumor agents. It details patient eligibility, tumor types, prognostic factors, efficacy measures, and response assessment criteria for these cancer drug studies.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Context:
Purpose:
Summary:
Impact: